Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination

European Journal of Surgical Oncology

Volumn 32, Issue 6, 2006, Pages 666-670

  de Bree, E ^a   Rosing, H ^b   Michalakis, J ^a,c   Romanos, J ^a   Relakis, K ^a   Theodoropoulos, P A ^c   Beijnen, J H ^b   Georgoulias, V ^a   Tsiftsis, D D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Docetaxel; Hyperthermia; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DEHYDRATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INSTILLATION; DRUG PENETRATION; FATIGUE; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; ILEUS; LEUKOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; SEPSIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; TAXOIDS;

EID: 33746233537     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.008     Document Type: Article

References (34)

1. McGuire III W.P., and Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89 Suppl. 3 (2003) S3-S8
2. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
3. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., and Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79 (2000) 211-215
4. Rose P.G., Fusco N., Fluellen L., and Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16 (1998) 1494-1497
5. Verschraegen C.F., Sittisomwong T., Kudelka A.P., Guedes E., Steger M., and Nelson-Taylor T. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18 (2000) 2733-2739
6. Markman M., Zanotti K., Webster K., Peterson G., Kulp B., and Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 91 (2003) 573-576
7. Rose P.G., Blessing J.A., Ball H.G., Hoffman J., Warshal D., DeGeest K., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 (2003) 130-135
8. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
9. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4 (2004) 277-283
10. Hofstra L.S., de Vries E.G.E., Mulder N.H., and Willemse P.H.B. Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev 26 (2000) 133-143
11. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 89 (1997) 480-487
12. Alberts D.S., Liu P.Y., Hannigan E.V., Rothenberg M.L., Muggia F., and Howell S.B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphomide for stage III ovarian cancer. N Engl J Med 335 (1996) 150-155
13. Markman M., Bundy B., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
14. Markman M., Reichman B., Hakes T., Jones W., Lewis Jr. J.L., Rubin S., et al. Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9 (1991) 1801-1805
15. Kohn E.C., Sarosy G., Bicher A., Link C., Christian M., Steinberg S.M., et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86 (1994) 18-24
16. Omura G.A., Bradt M.F., Look K.Y., Avarette H.E., Delmore J.E., Long H.J., et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study. J Clin Oncol 21 (2003) 2843-2848
17. Rowinsky E.K. The taxanes: dosing and schedule considerations. Oncology 11 (1997) 7-19
18. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis Jr. J.L., et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10 (1992) 1485-1491
19. Francis P., Rowinsky E., Schneider J., Hakes T., Hoskns W., and Markman M. Phase I feasibility and pharmacologic study of weekly paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13 (1995) 2961-2967
20. Hofstra L.S., Bos A.M.E., de Vries E.G.E., van der Zee A.G., Willemsen A.T., Rosing H., et al. Kinetic modelling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol 85 (2002) 517-523
21. Mohamed F., Marchetti P., Stuart O.A., Yoo D., and Sugarbaker P.H. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 29 (2003) 261-265
22. de Bree E., Rosing H., Beijnen J.H., Romanos J., Michalakis J., Georgoulias V., et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anti-Cancer Drugs 14 (2003) 103-110
23. Morgan Jr. R.J., Doroshow J.H., Synold T., Lim D., Shibata S., Margolin K., et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 9 (2003) 5896-5901
24. Michalakis J, Theodoropoulos T, Romanos J, de Bree E, Georgatos S, Tsiftsis DD. Combination of Taxol with hyperthermia: an in vitro study (abstract). In: 14th International Congress on Anti-Cancer Treatment, Paris, 1-4 February 2003, abstract book. p. 189-190.
25. Cividalli A., Livdi E., Ceciarelli F., Piscitelli M., Pasqualetti P., Cruciani G., et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 16 (2000) 61-71
26. Sharma D., Chelvi T.P., Kaur J., and Ralhan R. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 8 (1998) 240-244
27. Mohamed F., Stuart O.A., Gehlen O., Urano M., and Sugarbaker P.H. Docetaxel and hyperthermia: factors that modify thermal enhancement. J Surg Oncol 88 (2004) 14-20
28. Markman M., Brady M.F., Spirtos N.M., Hanjani P., and Rubin S.C. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 2620-2624
29. Markman M., Kulp B., Peterson G., Kennedy A., and Belinson J. Second-line therapy of ovarian cancer with paclitaxel administered by both the intravenous and intraperitoneal routes: Rationale and case reports. Gynecol Oncol 86 (2002) 95-98
30. Zylberberg B., Dormont D., Madelenat P., and Darai E. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol 25 (2004) 327-332
31. Rothenberg M.L., Liu P.Y., Brady P.S., Wilczynski S.P., Hannigan E.V., Wadler S., et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an Intergroup Phase II trial. J Clin Oncol 21 (2003) 1313-1319
32. Armstrong D.K., Bundy B.N., Baergen R., Lele S.B., Copeland L.J., Walker J., et al. Randomized phase III study of intravenous (iv) paclitaxel and cisplatin versus iv paclitaxel, intraperitoneal (ip) cisplatin and ip paclitaxel in optimal stage III epithelial ovarian cancer (oc): a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 21 (2002) #803
33. Orlando M., Huertas E., Salum G., Loza J., Colo F., Vilanova M., et al. Intraperitoneal hyperthermic chemotherapy as consolidation treatment for ovarian cancer in pathological complete remission. Proc Am Soc Clin Oncol 17 (1998) #1432
34. de Bree E., Romanos J., Michalakis J., Relakis K., Georgoulias V., Melissas J., et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 23 (2003) 3019-3028